IRVINE, Calif. — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, today announced that diagnostics industry veteran Jeff Hayes has been named Director of Sales for the Oncology market. Hayes brings more than 20 years of experience in the biopharmaceutical and cancer diagnostics industries to the position, having held marketing management positions with Schering-Plough and Eli Lilly, as well as sales management roles with US LABS (now a division of LabCorp) and PLUS Diagnostics.

Judd Jessup, President and CEO of CombiMatrix said, “Growing our cancer diagnostics business and list of clients is a key attribute of our strategy and will be an important revenue driver in the coming years. Having worked with Jeff in the past, I have first-hand knowledge of his skill and professional sales aptitude, especially when it comes to introducing new cancer testing services. I am certain that he is the right choice for this important role,” concluded Jessup.

Hayes will be heading the sales efforts of CombiMatrix’s DNAarray test portfolio that is focused on providing physicians with more informed test results to better treat their cancer patients. Test offerings include the DNAarray Heme Profile (for Hematologic malignancies), the DNAarray Tumor Profile (for various solid tumors) and the DNAarray Breast Profile.

CombiMatrix’s unique approach to analyzing a patient’s cancer provides both prognostic and therapeutic information by analyzing hundreds of key OncoGenes at once. With these personalized test results, physicians are assisted with key decision points. This testing can help an oncologist decide if a patient should receive treatment such as chemotherapy and can point toward the specific chemo-therapeutic agent that each patient’s unique tumor will best respond to, thereby improving treatment results.

Hayes will also be focused on strengthening the Company’s strategic partnerships as well as building direct-to-physician relationships and revenue streams.

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix Diagnostics (“CMDX”), is a CAP/CLIA certified molecular diagnostics laboratory offering comprehensive profiling of chromosomes and genes for both oncology and pre- and postnatal developmental disorders. CombiMatrix Diagnostics offers a comprehensive and proprietary analysis of cancer tumors at the DNA, or molecular level. CombiMatrix was the first commercial clinical laboratory in the United States to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to oncology patients and medical professionals. CombiMatrix also offers pre- and postnatal testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies. Additional information about CombiMatrix Corporation is available at www.combimatrix.com. Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.